(Q39281011)

10 September 2017

title

ADAM-17: a novel therapeutic target for triple negative breast cancer. (English)

1 reference

10 September 2017

P M McGowan

1

1 reference

10 September 2017

M Mullooly

2

1 reference

10 September 2017

F Caiazza

3

1 reference

10 September 2017

S Sukor

4

1 reference

10 September 2017

S F Madden

5

1 reference

10 September 2017

A A Maguire

6

1 reference

10 September 2017

A Pierce

7

1 reference

10 September 2017

E W McDermott

8

1 reference

10 September 2017

J Crown

9

1 reference

10 September 2017

N O'Donovan

10

1 reference

10 September 2017

M J Duffy

11

1 reference

10 September 2017

publication date

11 September 2012

1 reference

10 September 2017

1 reference

10 September 2017

volume

24

1 reference

10 September 2017

issue

2

1 reference

10 September 2017

page(s)

362-369

1 reference

Molecular portraits of human breast tumours

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Triple-Negative Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

EGFR associated expression profiles vary with breast tumor subtype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Role of ADAMs in cancer formation and progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

ADAMs: key components in EGFR signalling and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Characterization of (2R, 3S)-2-([[4-(2-butynyloxy)phenyl]sulfonyl]amino)-N,3-dihydroxybutanamide, a potent and selective inhibitor of TNF-alpha converting enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Exploration, normalization, and summaries of high density oligonucleotide array probe level data

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Entrez Gene: gene-centered information at NCBI

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Adjusting batch effects in microarray expression data using empirical Bayes methods

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

ADAM-17 expression in breast cancer correlates with variables of tumor progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Src: a potential target for the treatment of triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Chemotherapy-induced activation of ADAM-17: a novel mechanism of drug resistance in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Characterisation of breast cancer cell lines and establishment of a novel isogenic subclone to study migration, invasion and tumourigenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR ligands

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Use of molecular markers for predicting therapy response in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Synthetic lethality through combined Notch-epidermal growth factor receptor pathway inhibition in basal-like breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Dual blockade of EGFR and c-Met abrogates redundant signaling and proliferation in head and neck carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

ERBB3/HER3 and ERBB2/HER2 duet in mammary development and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Selective use of ADAM10 and ADAM17 in activation of Notch1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Structural features and biochemical properties of TNF-alpha converting enzyme (TACE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

TNF: a master switch for inflammation to cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

The role of TNF in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Selective inhibition of ADAM metalloproteases as a novel approach for modulating ErbB pathways in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDS279

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDS279

1 reference

10 September 2017

1 reference